Abstract Library

#4643 Characterisation of patients with progressive digestive NET during PRRT (LUTA-CHEC): A multicentre study from the Groupe des Tumeurs Endocrines

Introduction: PRRT with 177Lu-DOTATATE is a major treatment for metastatic digestive NETs. Most patients have prolonged progression-free survival, but around 20% experience early progression.

Conference:

Presenting Author: Haissaguerre M

Authors: Haissaguerre M, Hadoux J, Tlili G, Deshayes E, Lacombe M,

Keywords: GEP-NET, PRRT, early tumour progression,

#4573 Digestive neuroendocrine tumours: Patterns, pathways, and progress in personalised management

Introduction: Digestive neuroendocrine tumours (NETs), though rare, are increasingly diagnosed with their incidence rising. Histopathological examination is crucial for diagnosis and grading, based on cell differentiation and proliferation index. Often diagnosed late due to non-specific symptoms, these tumours may present with hormone hypersecretion. Updated classifications now allow better risk stratification and tailored treatments. Advances in imaging, particularly PETscans with somatostatin analogues have improved NET diagnosis and monitoring.

Conference:

Presenting Author: Bensetti Houari A

Authors: Bensetti Houari A, Remouche H, Belkharoubi K,

Keywords: Digestive neuroendocrine tumour, octreoscan, multidisciplinary approach,

#4554 Base on deep learning-integrated multimodal diagnostic framework for enhanced early detection of neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are a heterogeneous group of malignant neoplasms originating from neuroendocrine cells, commonly found in the digestive system, lungs, pancreas, and other organs. Due to their diverse clinical presentations and overlap with common diseases, the early diagnosis of NETs is challenging, often leading to misdiagnosis or delayed diagnosis at advanced stages.

Conference:

Presenting Author:

Authors: Ding Z, Li H, Tang Z, Chen Y, Li H,

Keywords: Neuroendocrine Tumour, Early Disease Screening, Multimodal Medical Data Analysis,

#4512 A deep learning-integrated multimodal diagnostic framework for enhanced early detection of neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) are a heterogeneous group of malignant neoplasms originating from neuroendocrine cells, commonly found in the digestive system, lungs, pancreas, and other organs. Due to their diverse clinical presentations and overlap with common diseases, the early diagnosis of NETs is challenging, often leading to misdiagnosis or delayed diagnosis at advanced stages. While current imaging techniques and biomarkers are useful in certain cases, their diagnostic sensitivity and specificity remain limited when used in isolation.

Conference:

Presenting Author:

Authors: Ding Z, Li H, Tang Z, Chen Y, Li H,

Keywords: Neuroendocrine Tumour, Multimodal Diagnostic algorithm, Deep Learning, Early Disease Screening,

#4460 Digestive neuroendocrine tumours G1 and G2: Experience of the medical oncology department at the Oran University Hospital Establishment 1st November 1954

Introduction: The histological classification of neuroendocrine tumours (NETs) remains complex, and their grading is a major prognostic factor, essential for guiding appropriate management. Moreover, NETs raise unresolved histogenetic questions. The treatment of grade 1 (G1) NETs primarily relies on somatostatin analogues, while grade 2 (G2) NETs, being more heterogeneous, may require management that includes chemotherapy or targeted therapy.

Conference:

Presenting Author:

Authors: Kehili H, Bengueddache A, Boumansour N, Larbi Bounsbia L, Bechikh A,

Keywords: Digestive Neuroendocrine Tumour, Grade 1, Grade 2, Somatostatin Analogue,